<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-29-2015-05928-241-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="SV">Studie av rollen som tarmens mikrobiota spelar i lever cirrhos f&#xF6;rloppet</narrative>
   <narrative xml:lang="EN">The role of the gut microbiome in the progression of liver cirrhosis</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and the second most common cause of death from cancer. Liver cirrhosis is the major risk factor for the development of HCC. In Ghana, liver cancer kills more adults than any other malignancy. Recent studies suggested that the intestinal microflora, which is the main source of portal vein Lipopolysaccharide, plays a critical role in this process. This joint effort with research and clinical experts in liver cancer, cirrhosis, microbiota, and epidemiology in Ghana, US and Sweden will help us to better understand the role of the intestinal microflora in the inflammatory process of liver cirrhosis and its progression. Our hypothesis is that the composition of the gut microbiome to which the liver is exposed at an enhanced level during liver cirrhosis, plays a role in the oncogenesis attributed to cirrhosis. We will study this using a prospective cohort study design including a group of liver cirrhosis patients and its matched healthy controls in Ghana. We will collect fecal samples from patients and controls and DNA will be extracted and 16S rRNA sequenced. If our hypothesis is proven correct, it opens up the possibility that simple probiotic regimens may be useful for prevention of liver cancer in low resource settings that would have a tremendous impact on poverty reduction. We estimate that the study will last 3 years and full results available in the year following the completion of the study.</narrative>
   <narrative xml:lang="SV">Levercancer &#xE4;r den sj&#xE4;tte vanligaste cancerformen i v&#xE4;rlden och den n&#xE4;st vanligaste d&#xF6;dsorsaken i cancer. Skrumplever &#xE4;r den st&#xF6;rsta riskfaktorn f&#xF6;r att utveckla levercancer. I Ghana d&#xF6;dar levercancer fler vuxna &#xE4;n n&#xE5;gon annan sjukdom. Nya studier tyder p&#xE5; att tarmflorans mikroflora spelar en avg&#xF6;rande roll i denna process. Denna gemensamma satsning med forskarexperter och kliniker i levercancer, skrumplever, mikrobiologi, i Ghana, USA och Sverige kommer hj&#xE4;lpa oss att b&#xE4;ttre f&#xF6;rst&#xE5; vilken roll tarmflorans mikroorganismer spelar i denna inflammatoriska process vid skrumplever. V&#xE5;r hypotes &#xE4;r att sammans&#xE4;ttningen av tarmen mikroorganismer f&#xF6;r vilken levern exponeras vid en f&#xF6;rh&#xF6;jd niv&#xE5; under skrumplever, spelar en viktig roll vid uppkomsten av levercancer. Vi kommer att studera detta i Ghana med hj&#xE4;lp av en epidemiologisk studie d&#xE4;r vi f&#xF6;ljer en grupp av patienter med skrumplever och dess matchade friska kontroller. F&#xF6;r att studera tarmens mikroflora kommer vi att samla in avf&#xF6;ringsprover fr&#xE5;n patienterna och kontrollerna som analyseras i labbet. Om v&#xE5;r hypotes &#xE4;r korrekt, &#xF6;ppnar detta upp m&#xF6;jligheten att enklare probiotiska behandling kan vara anv&#xE4;ndbara f&#xF6;r att f&#xF6;rebygga levercancer i l&#xE5;gresursl&#xE4;nder vilket skulle ha en stor betydelse f&#xF6;r fattigdomsminskning. Vi uppskattar att studien kommer att p&#xE5;g&#xE5; tre &#xE5;r.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Karolinska Institutet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-01-01" type="1"></activity-date>
  <activity-date iso-date="2016-01-01" type="3"></activity-date>
  <activity-date iso-date="2019-12-31" type="2"></activity-date>
  <activity-date iso-date="2019-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="GH" percentage="100">
   <narrative xml:lang="EN">Ghana</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">46748.0862502191</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">46800.0468000468</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">46027.8007916782</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-11-27"></transaction-date>
   <value currency="USD" value-date="2015-11-27">142360.5756112607</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">46748.0862502191</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-01-28"></transaction-date>
   <value currency="USD" value-date="2017-01-28">46800.0468000468</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-01-28"></transaction-date>
   <value currency="USD" value-date="2018-01-28">46027.8007916782</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <sida:contribution xmlns:sida="http://sida.se/ns/contribution#"></sida:contribution>
 </iati-activity>
</iati-activities>
